Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
04/2003
04/15/2003US6548644 Site protected protein modification
04/15/2003US6548556 Stable enzymatic wound debrider
04/15/2003US6548555 Solubility in small intestines; hydroxypropyl methyl cellulose acetate succinate polymer and zwitterion drug;
04/15/2003US6548513 (E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methyl -sulfonyl)amino)pyrimidin-5-yl)-(3R,5S)-3,5-dihydroxyhept-6-enoic acid or salt, stabilized by an inorganic salt having a multivalent cation, excluding synthetic hydrotalcite
04/15/2003US6548484 An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative ( forms a amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's and related diseases
04/15/2003US6548478 Virginiamycin mixture
04/15/2003US6548476 Dimeric inhibitors of influenza neuraminidase
04/15/2003US6548302 Polymers for delivery of nucleic acids
04/15/2003US6548275 Detection and treatment of infections with immunoconjugates
04/15/2003US6548083 Prolonged release active agent dosage form adapted for gastric retention
04/15/2003US6548081 Hyaluronic acid derivative is an N-acylurea that results from crosslinking hyaluronic acid with a multifunctional carbodiimide. reducing post-operative adhesion of tissues.
04/15/2003US6548079 Moxifloxacin formulation containing common salt
04/15/2003US6548071 Lyophilizate of lipid complex of water insoluble camptothecins
04/15/2003US6548067 Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof
04/15/2003US6548048 Encapsulation gases; medical diagnosis, therapy
04/15/2003CA2259698C Trovafloxacin mesylate tablet
04/15/2003CA2196150C Process for the preparation of medicated chewing gum provided with a pleasant taste independent from the active agent incorporated therein
04/15/2003CA2190485C Lacrimal gland specific emulsions for topical application to ocular tissue
04/15/2003CA2120599C Transdermal therapeutic systems containing crystallization inhibitors
04/15/2003CA2108018C Colloidal particles of water insoluble biologically active substances
04/15/2003CA2079315C Device and method for iontophoretic drug delivery
04/11/2003WO2002030961A1 Novel peptides
04/11/2003CA2425769A1 Novel peptides
04/10/2003WO2003029418A2 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
04/10/2003WO2003029291A2 Pegylated and diglycosylated erythropoietin
04/10/2003WO2003029214A1 Pseudopolymorphic forms of carvedilol
04/10/2003WO2003028990A1 Systems, methods and apparatuses for manufacturing dosage forms
04/10/2003WO2003028989A1 Systems, methods and apparatuses for manufacturing dosage forms
04/10/2003WO2003028776A1 Sanitary napkins with hydrophobic lotions
04/10/2003WO2003028767A2 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions and methods
04/10/2003WO2003028766A1 Water-in-oil emulsions comprising vinyl polymers carrying acidic groups in side chains, compositions, and methods
04/10/2003WO2003028765A1 Injections for eye tissue containing drug bound to polyethylene glycol
04/10/2003WO2003028764A1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
04/10/2003WO2003028743A1 Storage-stable fibrinogen solutions
04/10/2003WO2003028742A1 Strontium compound for treatment of sub-dermal soft tissue pain
04/10/2003WO2003028723A1 Pharmaceutical compositions for percutaneous absorption containing fused imidazopyridine derivatives
04/10/2003WO2003028718A1 Novel formulations of carvedilol
04/10/2003WO2003028716A1 Aqueous ecabet sodium solution preparation
04/10/2003WO2003028713A2 3,4-methylenedioxy-substituted chalcones as therapeutic agents
04/10/2003WO2003028708A1 Timed, sustained release multi-particulate dosage forms of propranolol
04/10/2003WO2003028707A1 Solid compositions comprising ramipril
04/10/2003WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide
04/10/2003WO2003028704A1 Extended release pharmaceutical composition containing metformin
04/10/2003WO2003028702A1 Ibuprofen salt emulsifiers and cream formulations containing same
04/10/2003WO2003028700A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials
04/10/2003WO2003028699A1 Compositions used to alleviate xerostomia and to treat disorders associated with same
04/10/2003WO2003028697A2 Liposome loading with metal ions
04/10/2003WO2003028667A2 Semisolid topical hormonal compositions and methods for treatment
04/10/2003WO2003028662A2 A method of producing a processed kava product having an altered kavalactone distribution and processed kava products produced using the same
04/10/2003WO2003028656A2 Adjuvant compositions
04/10/2003WO2003028654A2 Storage-stable human fibrinogen solutions
04/10/2003WO2003028648A2 Veterinaire florfenicol formulation that is syringeable under cold weather conditions
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028619A2 Systems, methods and apparatuses for manufacturing dosage forms
04/10/2003WO2003028600A1 Wipe formulation
04/10/2003WO2003028589A1 Pla/plga oligomers combined with block copolymers for enhancing solubility of a drug in water
04/10/2003WO2003028527A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
04/10/2003WO2003028492A1 Encapsulated materials
04/10/2003WO2003028479A1 Flavor-active peptides
04/10/2003WO2003007971A9 Improved heteropolymer complexes and methods for their use
04/10/2003WO2003004062A9 Pharmaceutical formulations and ligands for use therein; mimetics for uea-1
04/10/2003WO2003002598A3 Peptides for use as translocation factors
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2003000193A3 Covalent coupling of botulinum toxin with polyethylene glycol
04/10/2003WO2003000175A3 Pediatric formulation of gatifloxacin
04/10/2003WO2002100348A8 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
04/10/2003WO2002098365A3 Conditioned cell culture media and uses thereof
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002085326A3 Large, porous particles produced controlling humidity during a spray drying process
04/10/2003WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure
04/10/2003WO2002083079A9 Aerosol compositions containing formoterol for delivery to the lungs via nebulization
04/10/2003WO2002074238A3 Water soluble and palatable complexes
04/10/2003WO2002070070A3 Compositions having improved bioavailability of eletriptan
04/10/2003WO2002065988A3 Terminally-branched polymeric linkers and polymeric conjugates containing the same
04/10/2003WO2002060412A3 Stabilised polymeric aerosols for pulmonary gene delivery
04/10/2003WO2002055705A3 Proteins and nucleic acids encoding same
04/10/2003WO2002053173A3 Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases
04/10/2003WO2002045687A3 Topical alcoholic solution of a salicylic acid derivative and acemannan
04/10/2003WO2002043767A8 Improved oral delivery of peptides using enzyme-cleavable membrane translocators
04/10/2003WO2002042414A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
04/10/2003WO2002009678A3 Charged phospholipid compositions and methods for their use
04/10/2003WO2001083693A3 Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
04/10/2003US20030069400 Hapten-carrier conjugate for use in the treatment of cocaine addiction
04/10/2003US20030069395 Serum albumin conjugate for use in the transfer and delivery of therapeutic agent to target
04/10/2003US20030069318 Salts of analgesic substances in oil, and methods of making and using the same
04/10/2003US20030069313 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
04/10/2003US20030069307 Oxidation resistance; free radical scavenger; foods, drugs, cosmetics
04/10/2003US20030069301 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
04/10/2003US20030069217 Methods of prevention and treatment of ischemic damage
04/10/2003US20030069213 Oral preparation
04/10/2003US20030069211 Injectable pamidronate disodium
04/10/2003US20030069207 Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration
04/10/2003US20030069206 Chitosan; packaging; and instructions indicating that the chitosan may be consumed with food for reducing absorption of lipids by the digestive system
04/10/2003US20030069205 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate.
04/10/2003US20030069203 Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
04/10/2003US20030069183 Lyophilized HGF preparations
04/10/2003US20030069173 Peptide-enhanced transfections
04/10/2003US20030069170 Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
04/10/2003US20030068812 Immune modulation device for use in animals
1 ... 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 ... 1712